Streetbeat News

Stock Prices

UPC

Universe Pharmaceuticals shares have been halted after experiencing an 11.80% increase in their stock price.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:26 pm

BB

Blackberry shares have resumed trading after a temporary halt. This development may influence investor sentiment and trading activity in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:26 pm

AMPS

ATNF

NVAX

USB

U.S. stocks rose with the Dow Jones gaining over 250 points. U.S. Bancorp reported better-than-expected earnings, while other companies like 180 Life Sciences and Altus Power saw significant stock movements. Novavax faced a setback with an FDA clinical hold.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 4:26 pm

ASML

Steve Weiss announced on CNBC that he has sold his shares in ASML. This decision could influence investor sentiment and potentially impact ASML's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:24 pm

RBLX

The Bear Cave's Edwin Dorsey accuses Hindenburg Research of plagiarism, claiming they used his research on Roblox without credit. Hindenburg's Nate Anderson denies the allegations, stating he never used Dorsey's work. The dispute centers around similar reports on Roblox and other companies.

Portfolio Pulse from Adam Eckert

October 16, 2024 | 4:23 pm

EPAC

Enerpac Tool Group's shares declined following the release of disappointing Q4 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:23 pm

LRMR

Larimar Therapeutics shares rose after Oppenheimer initiated coverage with an Outperform rating and a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:23 pm

HCM

HUTCHMED shares rose following the announcement of positive high-level results from the SAVANNAH Phase II trial.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:22 pm

UNH

UnitedHealth Group Inc (NYSE:UNH) reported better-than-expected Q3 earnings, but analysts have cut forecasts due to higher medical costs and other pressures. Despite the earnings beat, the company's Medical Loss Ratio was worse than expected, leading to reduced price targets from several analysts.

Portfolio Pulse from Priya Nigam

October 16, 2024 | 4:18 pm

WVE

Wave Life Sciences shares rose after the company announced successful therapeutic RNA editing in humans from its RestorAATion-2 trial of WVE-006 for Alpha-1 antitrypsin deficiency.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:17 pm